J Chromatogr B Analyt Technol Biomed Life Sci.
2005 Jan 25;814(2):303-8.
Simultaneous determination of benazepril hydrochloride and benazeprilat
in plasma by high-performance liquid chromatography/electrospray-mass
spectrometry.
Xiao W, Chen B, Yao S, Cheng Z.
Key Laboratory of Chemical Biology and Traditional Chinese Medicine
Research (Hunan Normal University), Ministry of Education, Hunan
Normal University, Changsha 410081, PR China.
An analytical method for simultaneous determination of benazepril
and its active metabolite, benazeprilat, in human plasma by high-performance
liquid chromatography/electrospray-mass spectrometry was developed
and validated. Rutaecarpine was selected as the internal standard.
The separation was achieved on a C(18) column with acetonitrile
and aqueous solution (0.1% formic acid) as mobile phase with a
gradient mode. The quantification of target compounds was using
a selective ionization recording at m/z 425.5 for benazepril,
m/z 397.5 for benzeprilat and m/z 288.3 for rutaecarpine. The
correlation coefficients of the calibration curves were better
than 0.992 (n = 6), in the range of 6.67-666.67 ng/ml for benazepril
and benazeprilat. The inter- and intra-day accuracy, precision,
linear range had been investigated in detail. The method can be
used to assess the bioavailability and pharmacokinetics of the
drug.
Adv Perit Dial. 2003;19:10-4.
Effects of antihypertensive drugs on peritoneal vessels in hypertensive
dogs with mild renal insufficiency.
Ishida Y, Tomori K, Nakamoto H, Imai H, Suzuki H.
Department of Nephrology, Saitama Medical School, Saitama, Japan.
The transport capacity of any membrane depends on its surface
area and permeability. In addition, peritoneal capillaries are
probably barriers to solute transport. Although no decisive use
of antihypertensive drugs has been reported in continuous ambulatory
peritoneal dialysis (CAPD) patients with hypertension, those drugs
are known to have various effects on vessels. In the present study,
we used a charge-coupled-device (CCD) camera in renovascular hypertensive
dogs with mild renal insufficiency to investigate the effects
of various antihypertensive drugs on the peritoneal capillaries.
Renovascular hypertension was induced in the dogs by placing silver
clips on both renal arteries to create 90% occlusion. After confirmation
of elevation of blood pressure (usually 20 days after the operation),
each dog's abdomen was opened while the animal was under general
anesthesia. Using a CCD camera, the diameters of the small arteries
of the peritoneum were measured after 3 days' oral administration
of a placebo (n = 5); or of 8 mg CS866, a selective angiotensin
II type 1 receptor blocker (n = 5); or of 10 mg benazepril, an
angiotensin-converting enzyme inhibitor (n = 5); or of 10 mg amlodipine,
a calcium antagonist (n = 5). In dogs receiving CS866, blood pressure
decreased to 128 +/- 6 mmHg from 160 +/- 6 mmHg (p < 0.01).
A similar decrease in blood pressure was observed with the use
of the other drugs. The diameter of the small vessels increased
by 28% +/- 6% in dogs receiving CS866 and by 24% +/- 5% in dogs
receiving benazepril, as compared with 3% +/- 3% in dogs receiving
the calcium antagonist. These data clearly demonstrate that blockade
of the renin-angiotensin system produces an increase in solute
clearance in hypertensive dogs with mild renal insufficiency and
that such blockade may be applicable as therapy for hypertensive
patients on CAPD.
Am J Kidney Dis. 2004 Feb;43(2):260-8.
Low-dose dual blockade of the renin-angiotensin system in patients
with primary glomerulonephritis.
Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski
B.
Department of Nephrology, Transplantology, and Internal Medicine,
Medical University of Gdansk, Gdansk, Poland.
BACKGROUND: Treatment with agents interfering with the renin-angiotensin
system retards the progressive course of proteinuric chronic renal
disease. However, because of unwanted effects associated with
such therapy, some patients cannot be treated with these drugs
at all or may be administered only very small doses. To find an
optimal nephroprotective strategy for these patients, we compared
antiproteinuric effects of combination therapy with an angiotensin-converting
enzyme inhibitor and angiotensin II type 1 receptor antagonist
in very small doses with treatment with either agent alone at
greater, but not maximal, doses. We compared the concomitant use
of benazepril, 5 mg, and losartan, 25 mg, and monotherapy with
these agents in doses 2-fold greater. METHODS: This is a randomized,
open, crossover study of 3 treatments in 3 periods of 4 months
each. Twenty-four patients with primary glomerulonephritis and
nonnephrotic proteinuria, recognized previously as not able to
be administered high doses of drugs from these classes, completed
the protocol. RESULTS: Combined therapy decreased 24-hour proteinuria
(-45.54% versus baseline) more effectively than either losartan
(-28.17%; analysis of variance, P < 0.01) or benazepril (-20.19%;
analysis of variance, P < 0.001) alone. Subgroup analysis showed
that antiproteinuric effects of combination therapy, as well as
losartan or benazepril alone, were significantly greater in patients
with basal proteinuria greater than 2 g/24 h than in those with
proteinuria less than this value (P < 0.001, P < 0.01, and
P < 0.05, respectively). All therapies significantly decreased
blood pressure (BP) compared with baseline, but there were no
differences between treatments in BP changes. CONCLUSION: The
study shows that combination therapy with very small doses of
losartan and benazepril was more effective in reducing proteinuria
than greater doses of either agent in monotherapy, and this greater
antiproteinuric efficacy was independent of changes in BP.
J Clin Hypertens (Greenwich). 2003 Jul-Aug;5(4
Suppl 3):4-11.
Rationale for combination therapy as initial treatment for hypertension.
Giles TD.
Louisiana State University School of Medicine, New Orleans, LA
70112, USA.
Recent hypertension guidelines recommend initiating antihypertensive
therapy with a combination of two or more agents in patients whose
blood pressure exceeds their appropriate blood pressure goal by
20/10 mm Hg. This recommendation is based on the knowledge that
the majority of patients with blood pressures of this magnitude
will not achieve sufficient blood pressure reduction with monotherapy.
Further, compared with high-dose monotherapy, combination therapy
is often associated with fewer adverse effects and, for this reason,
may improve patient adherence. Bringing patients to blood pressure
goal quickly is likely to improve clinical outcomes. This article
discusses the rationale for using combination antihypertensive
therapy as initial therapy for high blood pressure in selected
patients and reviews data from a study of 364 high-risk patients
with Stage 2 hypertension in which a fixed-dose combination product
(amlodipine besylate/benazepril HCl) proved more successful as
initial therapy than high-dose monotherapy (amlodipine besylate)
in reducing blood pressure.
Ter Arkh. 2003;75(4):54-8.
Comparative effectiveness of lotensin and capoten in patients
with chronic cardiac failure.
Zadionchenko VS, Timofeeva NIu, Li VV, Suvorova SS.
AIM: To compare clinical response to captopril (capoten) vs benazepril
(lotensin) in patients with chronic cardiac failure (CCF) as well
as their influence on central hemodynamics, some indices of platelet
hemostasis, myocardial ischemia degree, exercise tolerance. MATERIAL
AND METHODS: 54 patients with CCF (NYHA FC II and III) entered
the trial. 26 patients received captopril (capoten) in a dose
25-75 mg/day (group 1) while 28 patients were given benazepril
(lotensin) in a dose 5-30 mg/day for 4 weeks (group 2). Group
II was treated for the following 24 weeks. The results were assessed
with electro- and echocardiography, bicycle exercise test, platelet
aggregation measurement and by clinical symptoms. RESULTS: A positive
clinical response was registered to both the drugs which improved
the functional class, exercise tolerance, platelet aggregation,
reduced the number of arrhythmia and myocardial ischemia episodes.
Long-term treatment with lotensin resulted in further improvement
of clinical and laboratory indices. Side effects, in which lotensin
discontinuation is needed, were absent. Lotensin was more potent
than capoten in reducing episodes of ST expression on ECG and
episodes of painless myocardial ischemia.
Eur J Clin Pharmacol. 2003 Aug;59(4):271-5. Epub
2003 Jun 27.
Effect of benazepril amlodipine combination on fibrinolysis in
hypertensive diabetic patients.
Fogari R, Preti P, Lazzari P, Corradi L, Zoppi A, Fogari E, Mugellini
A.
Department of Internal Medicine and Therapeutics, Clinica Medica
II, IRCCS Policlinico San Matteo, University of Pavia, Piazza
Golgi 2, 27100, Pavia, Italy.
OBJECTIVE. The aim of this study was to compare the effects of
benazepril and amlodipine in monotherapy versus in combination
with plasma t-PA and PAI-1 activity in hypertensive type-2 diabetic
patients. METHODS. After an initial 6-week wash-out, single-blind
placebo period, 38 patients, 17 men and 21 females, were randomly
assigned to receive benazepril 10 mg o.d. or amlodipine 5 mg o.d.
or their combination o.d. at the same dosage for 6 weeks in three
crossover periods each separated by a 2-week placebo wash-out
period (3x3 latin square). At the end of the placebo run-in period
and of each treatment period, BP, plasma PAI-1 and tPA activity
were evaluated. RESULTS. Both benazepril and amlodipine were similarly
effective in reducing systolic blood pressure (SBP) (-17.6 mmHg
with benazepril and -19.8 mmHg with amlodipine; P<0.001 versus
placebo), and diastolic blood pressure (DBP) (-11.1 mmHg, -13.2
mmHg, respectively). Combination therapy produced greater reduction
in SBP/DBP values (-28.3/-20.5 mmHg; P<0.001 versus placebo,
P<0.01 versus benazepril and amlodipine). Benazepril monotherapy
significantly decreased plasma PAI-1 activity (-8.4 IU/ml, P<0.05)
while it did not influence t-PA activity (+0.02 IU/ml). Amlodipine
monotherapy produced a significant increase in t-PA activity (+0.27
IU/ml, P<0.05) while it did not influence PAI-1 activity (+0.8
IU/ml). The amlodipine/benazepril combination produced both a
significant decrease in plasma PAI-1 activity (-8.7 IU, P<0.05)
and a significant increase in t-PA activity (+0.26 IU/ml, P<0.05).
CONCLUSIONS. These data suggest that in hypertensive type-2 diabetic
patients, a population with an impaired fibrinolysis, the benazepril/amlodipine
combination, may improve the fibrinolytic balance more than the
single drugs.
J Assoc Physicians India. 1998 Mar;46(3):283-5.
An open clinical trial of benazepril--a new ACE inhibitor in mild-moderate
hypertension.
Karnik ND, Oza YK, Sane SP, Kaushik R, Bhatt AD, Chawla KP, Vaidya
AB, Yajnik VH, Khokhani RC.
LTM Medical College and Hospital, Mumbai.
Benazepril hydrochloride, a new non-sulfhydryl ACE inhibitor (ACEI)
was studied in a titrated dose of 10 mg-20 mg once a day for 6
weeks in 42 mild to moderate adult hypertensive patients with
sitting diastolic blood pressure (SDBP) 95-114 mm Hg. The pre-drug
SDBP(mean +/- SE) of 102.5 +/- 0.8 mm Hg showed a significant
reduction to 87.5 +/- 0.93 mm Hg at the end of treatment. BP was
controlled (SDBP < or = 90 mm Hg) in 34 (81%) patients and
a drop of at least 10 mm Hg from the pre-treatment SDBP value
was noted in 34 (81%) patients. Common adverse reaction was cough
in 8(19%) patients. Clinically significant changes in laboratory
evaluations were not seen in any patient. Study showed that benazepril
in a dose range of 10 to 20 mg per day is an effective agent for
treatment of mild to moderate hypertension.
Ann Cardiol Angeiol (Paris). 1998 Jan;47(1):33-41.
Antihypertensive action and predictive factors of efficacy of
benazepril in mild-to-moderate hypertension: clinical trial in
general medical practice on 16,987 patients.
Haziza HM, Francillon A, Mottier D, Heintzmann F, Serrurier D.
Service de Cardiologie, Hopital Saint-Antoine, Paris.
The aim of the study was to evaluate in general practice, in a
large and unselected population of patients, the efficacy and
safety of benazepril associated or not with hydrochlorothiazide
(HCTZ) and to identify clinical and demographic predictive factors
of antihypertensive efficacy. In this open uncontrolled study,
16,987 patients with mild to moderate hypertension were included
by 5350 GPs. They received benazepril (BNZ) 10 mg once daily for
8 weeks. If sitting DBP remained > 90 mmHg after 4 weeks, HCTZ
12.5 mg once a day was then added for the last 4 weeks. RESULTS:
In the intent to treat analysis, 54.5% of patients, after 4 weeks,
and 80.6% of patients after 8 weeks, were controlled (DBP <
90 mmHg). Mean sitting DBP decreased from 100.5 +/- 5.5 mmHg (baseline)
to 86.7 +/- 7.5 mmHg after 4 weeks and to 82.5 +/- 6.5 mmHg after
8 weeks. Mean SBP decreased from 169.5 +/- 13.1 mmHg to 150.5
+/- 12.5 mmHg after 4 weeks and to 145.0 +/- 10.9 mmHg after 8
weeks. Of the 16,900 patients included in the safety analysis,
853 (5.0%) dropped out of the study, 504 (3.0%) for adverse events
(AE). The most frequent AE were: cough (3.5%), headache (0.9%),
dizziness (0.8%), asthenia (0.6%) and nausea (0.5%). 13 deaths
were observed during the study, mainly due to stroke or cancer.
Six cases of raised serum creatinine level, 3 cases of angio-oedema
and 2 cases of hepatitis were also reported. After 8 weeks of
treatment, the main predictors of therapeutic response (DBP) were:
recently discovered hypertension (86.3% of controlled DBP), regular
exercise (85.5%) and age < 50 years (84.6%). Conversely: obesity,
diabetes mellitus (77.9%), previously treated with several drugs
(75.2%) and initial DBP > or = 105 mmHg (74.5%) were not predictive.
Predictive factors emerging from logistic regression were : baseline
DBP (< 105 mmHg), history of hypertension, body mass index,
initial treatment of hypertension (no treatment--one drug--several
drugs) and age. CONCLUSION: This large-scale study confirms, the
antihypertensive efficacy and good tolerability of benazepril
alone or associated with hydrochlorothiazide in general practice.
Clin Nephrol. 1998 Aug;50(2):108-12.
Effects of benazepril on insulin resistance and glucose tolerance
in uremia.
Wu Z, Bao X.
Zhong Shan Hospital, Shanghai Medical University, PR China.
This study tested whether the angiotensin-converting enzyme inhibitor
(ACEI) benazepril can improve the insulin resistance and glucose
tolerance in uremia. Fifteen uremic hypertensive patients were
treated with benazepril in a dose of 10-20 mg per day for ten
weeks, and ten healthy subjects, matched in age, sex ratio and
body mass index (BMI), served as the control group. Before and
after the treatment, an oral 75 g glucose tolerance test (OGTT)
and insulin release test (IRT) were performed in two groups above,
and the blood glucose and serum insulin concentrations at 0, 60,
120 and 180 minutes after glucose load were examined, and the
insulin glycoregulatory activity, including insulin sensitivity
index (ISI), glucose uptake rate (M), total areas under the glucose
and insulin curves during OGTTs (AUCG AUCINS), was calculated.
The changes of serum potassium and renal function before and after
treatment were observed. It showed that (1) benazepril could reduce
blood pressure significantly (SBP decreased from 174.8 +/- 12.0
mmHg to 151.5 +/- 9.0 mmHg, p <0.001; DBP decreased from 108.0
+/- 8.2 mmHg to 95.3 +/- 9.0 mmHg, p <0.001). The total response
rate was 86.7%. (2) After treatment with benazepril for ten weeks,
the blood glucose and serum insulin concentrations after glucose
load and AUCG, AUCINS values in the uremic patients were significantly
lower than before treatment, but were still significantly higher
than in the controls. The values of ISI and M in the uremic patients
after treatment were much higher than before treatment, but were
still significantly lower than in the control subjects. (3) The
differences of serum potassium and creatinine levels before and
after treatment were not significant. These findings indicate
that benazepril can not only reduce blood pressure effectively
and safely, but also partly improve insulin resistance, hyperinsulinemia
and glucose intolerance in uremia.
Hunan Yi Ke Da Xue Xue Bao. 1998;23(1):87-9.
Effects of lotensin and nitrendipine on plasma fibrinogen and
platelet aggregation in hypertensive patients.
Pan R, Sun M, Zhou H, Jia Z.
Department of Medicine, Xiangya Hospital, Hunan Medical University,
Changsha.
Plasma fibrinogen and platelet aggregation were measured by turbidimetric
immunoassay, turbidimetry in 47 hypertensive patients and 20 normotensive
control subjects. Among the 47 hypertensives, 24 cases were received
lotensin and 23 nitrendipine. The plasma fibrinogen was increased
and platelet aggregation enhanced in hypertensive patients before
treatment. Platelet aggregation decreased after 8 weeks of treatment
with lotensin or nitrendipine respectively. Lotensin decreased
plasma fibrinogen whereas nitrendipine did not. It was concluded
that both lotensin and nitrendipine decreased platelet aggregation;
lotensin decreased plasma fibrinogen but nitrendipine did not.
Am J Cardiol. 1998 Jun 1;81(11):1368-70.
Effect of benazepril on complex ventricular arrhythmias in older
patients with congestive heart failure, prior myocardial infarction,
and normal left ventricular ejection fraction.
Aronow WS, Mercando AD, Epstein S.
Hebrew Hospital Home, Bronx, New York 10475, USA.
Sixty patients, mean age 82 +/- 8 years, with congestive heart
failure, prior myocardial infarction, normal left ventricular
ejection fraction, and > or = 30 ventricular premature complexes
per hour detected by 24-hour ambulatory electrocardiograms, and
who were treated with diuretics, were randomized to treatment
with benazepril 20 to 40 mg/day (30 patients) or to no benazepril
(30 patients). At a median of 6 months after treatment, follow-up
24-hour ambulatory electrocardiograms showed that compared with
no benazepril, benazepril caused no significant reduction in the
number of ventricular premature complexes per hour or in the number
of runs of ventricular tachycardia per 24 hours.
Orv Hetil. 1997 Jul 6;138(27):1737-42.
Experience with benazepril, a long-acting ACE inhibitor, in the
management of diabetic hypertension.
Winkler G, Hajos P, Pal B, Toth J.
Fovarosi Szent Janos Korhaz I. Belosztaly, Budapest.
The therapeutic advantage of the long acting ACE-inhibitor benazepril
in a 12 weeks intervention period on 23 diabetic (3 IDDM, 20 NIDDM)
patients with essential hypertension was studied. Participants-giving
informed consent before beginning the study-on the base of repeated
casual blood pressure measurements were divided into "slightly"
(n = 8) and "moderately" (n = 15) hypertonic groups.
Type of diabetes, time elapsed since its manifestation, actual
antidiabetic therapy, period of existence of the hypertension
(newly discovered vs known and treated for a time) were independent
from the point of view of entering the study. Initial dose of
benazepril was 5-10 mg/day depending on the blood pressure level,
followed by a stepwise dose elevation according to the control
investigations (at weeks 2, 4, 8 and 12 casual blood pressure
control, at weeks 4 and 12 ambulantory blood pressure monitoring,
ABPM as well) to a maximal daily dose of 20 mg. In the majority
of patients benazepril was given in a morning single dose, in
some cases because of a better tolerability divided into two parts.
20 patients received benazepril in monotherapy, 3 patients combined
with other antihypertensive preparations. Parameters indicating
severity of hypertension-hypertonic time index, hyperbaric impact-showed
significant improvement already at week 4 when analysed in the
total of patients and the moderately hypertonic group respectively.
As a tendence the same was observed also in the slightly hypertonic
group. No remarkable side effects, or alterations of the metabolic
state and in the investigated laboratory parameters appeared.
Based on these results benazepril is an effective choice in the
treatment of diabetic hypertensive patients.
Orv Hetil. 1996 Sep 8;137(36):1973-8.
Efficacy of benazepril monotherapy in moderate essential hypertension
studied by automatic ambulatory blood pressure monitoring.
Pall D, Juhasz A, Karanyi Z.
Debreceni Orvostudomanyi Egyetem I. Belgyogyaszati Klinika.
Authors examined the effects of benazepril, regarding the length
of effectiveness by ambulatory blood pressure monitoring (ABPM),
drug tolerable, and the compliance of patients in mild to moderate
essential hypertension. 14 patients were treated with benazepril
monotherapy. Six of them were newly diagnosed, and the rest had
already been treated for hypertension. At the start, after six
and 12 weeks, 24-hour monitoring was performed. Casual blood pressure
(BP) measurements and detection of side-effects were also performed
at 3rd and 9th-week. Prior the study the average daytime BP measured
by ABPM was 149.1 +/- 7.7/96.6 +/- 4.7 mmHg. 10 mg of benazepril
was first administered in the morning. By the end of the sixth
week the average BP was significantly decreased (daily average:
139.1 +/- 9.9/88.2 +/- 7.6 mmHg). The daytime diastolic average
BP of 8 patients was lower than 90 mmHg and the other's daily
dose was raised to 20 mg. During the 12th-week we found optimal
tension in 11 patients, while in two others there was also a significant
decrease. The daily average BP was 134.7 +/- 7.5/85.6 +/- 6.6
mmHg. In comparison the data at the beginning of the study here
was significant decrease in the 24-hour, daytime and night-time
BP, in the hypertension time-index and the hyperbaric impact,
both in systolic and diastolic levels. During the 12th-week period
the diurnal index was unchanged. The early morning BP decreased
by the end of the 3rd month from 148.6 +/- 14.1/98.5 +/- 11.7
mmHg to 135.2 +/- 13.5/93.4 +/- 11.2 mmHg. Sustained side-effect
did not occur. The patient's compliance to benazepril was excellent.
Authors conclude that benazepril monotherapy lowered in 92.8%,
and normalized in 78.5% the blood pressure of patients suffering
from mild to moderate essential hypertension. The unchanged diurnal
index, and the decrease in the early morning blood pressure suggest
the 24-hour effect of benazepril.
Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jul;56(1):12-22.
Short-term and long-term effects of benazepril in mild to moderate
hypertensives.
Chen CH, Hsu TL, Lin SJ, Ting CT, Chou P, Wang SP, Yin FC, Chang
MS.
Division of Cardiology, Veterans General Hospital-Taipei, Taiwan,
R.O.C.
BACKGROUND: Benazepril hydrochloride is a non-sulfhydryl-containing,
angiotensin-converting enzyme (ACE) inhibitor. The short-term
and long-term antihypertensive effects of benazepril remain to
be established in Chinese. METHODS: Hypertensive subjects with
diastolic blood pressure 95-110 mmHg, after two week placebo run-in
first, entered a four-week double-blind phase with treatment of
benazepril 10 mg once daily or captopril 25 mg three times daily,
then received one-year open treatment of benazepril 10 mg daily
with or without diuretics. Ambulatory blood pressure monitoring
was performed at the end of placebo run-in, after four-week double-blind
phase, and after one-year open treatment. RESULTS: Of the 75 subjects
(41 male, 34 female, mean age 57 +/- 12 years, range 34-88 years)
who completed the double-blind phase, 42 subjects finished the
one-year extension phase. Reasons for withdrawal from the study
included irritable cough (16, 21%), hypotension (1, 1%), and poor
compliance (16, 21%). During the short-term double-blind phase,
benazepril reduced clinic and mean 24-h ambulatory blood pressure
by -21/-10 mmHg and by -17/-10 mmHg respectively, and captopril
by -21/-13 mmHg and by -17/-10 mmHg respectively. After one-year
open treatment by benazepril for the 42 subjects, the one-year
average clinic blood pressure was 134/88 mmHg (155/104 mmHg at
entry and 135/93 mmHg at the end of the double-blind phase), and
the mean 24-h ambulatory blood pressure was 137/87 mmHg (149/95
mmHg at entry and 132/84 mmHg at the end of the double-blind phase).
CONCLUSIONS: The antihypertensive effect of benazepril 10 mg daily
with or without diuretics is not significantly different from
that of captopril 75 mg daily in the short-term and can reasonably
be maintained for one year.
Ter Arkh. 1995;67(9):56-8.
The antihypertensive activity of benazepril in the long-term treatment
of hypertension patients and its effect on adrenal cortical function
Olbinskaia LI, Golubev SA, Bolshakova TD, Anastas'ina GV, Buniatian
AF, Nosova AA.
Changes in arterial hypertension, heart rate and adrenocortical
hormones (11-OCS, aldosteron, progestins) in the blood and 24-h
urine were followed up in the course of 24-week use of angiotensin-converting
enzyme inhibitor benazepril (10-20 mg once a day) in 24 patients
with mild and moderate essential hypertension (EH) included in
a placebo-controlled randomized study. A 2 and 24-week antihypertensive
response was achieved in 75 and 71% of patients, respectively.
24-h urinary excretion of corticosteroids before the treatment
was increased. After the treatment benazepril reduced excretion
of 11-OCS by 42%, but not of aldosteron the levels of which decreased
only within the first 2 weeks of treatment. The above trends in
changes of gluco- and mineralocorticoid activity should be taken
into consideration in long-term treatment of EH with inhibitors
of angiotensin-converting enzyme.
ANNA J. 1993 Apr;20(2):187-8.
Benazepril: a new ACE inhibitor.
Bell J.
Benazepril (Lotensin) is an ACE inhibitor that can be safely used
in renal and liver disease. Statistical analysis of both single
and repeated 10 mg oral doses shows no significant difference
in action between young patients and those over 55. All ACE inhibitor
drugs are in a homogenous class. One advantage that benazepril
has over the others is convenience. It can be taken any time of
day, with or without food, and most often is only needed once
a day. This is important to our patients who are on multiple medication
regimens. There are no clinically important pharmacologic interactions
with digoxin, warfarin, naproxen, cimetidine, hydrochorothiazide,
furosemide, propranolol, atenolol, or chlorthalidone.
